GGrantIndex
Sort

40,608 grants matching prostate cancer

The LUCINDA Trial

$1,603,736
Tracy A. Butler · New York University School Of Medicine · R01 · FY2018 · AG

TARGETING MNK/GRP78 PATHWAY TO DISRUPT PROTEOSTASIS REWIRING IN CASTRATION-RESISTANT PROSTATE CANCER

$1,602,137
University Of Kentucky Research Foundation, The · · FY2025 · Defense Health Agency

Magnetic Resonance Imaging-Guided Cancer Interventions

$1,601,962
Kim Butts Pauly · Stanford University · P01 · FY2014 · CA

UCLA SPORE in Prostate Cancer

$1,599,812
Robert E Reiter · University Of California Los Angeles · P50 · FY2023 · CA

HOWARD UNIVERSITY CANCER CENTER/JOHNS HOPKINS CANCER CENTER PARTNERSHIP

$1,599,440
Lucile L Adams-Campbell · Howard University · U54 · FY2006 · CA

Epidemiology of Putative Causal Variants in the Multiethnic Cohort

$1,599,270
Loic Le Marchand · University Of Hawaii At Manoa · U01 · FY2011 · HG

PLCO Trial Etiologic and Early Marker Study

$1,598,190
Steven Moore · Division Of Cancer Epidemiology And Genetics · ZIA · FY2023 · CA

Genetics of Prostate Cancer in Africa

$1,598,130
Timothy R Rebbeck · Dana-Farber Cancer Inst · U01 · FY2019 · CA

Interrogating Epigenetic Changes in Cancer Genomes

$1,596,781
Tim H.-M. Huang · Ohio State University · U54 · FY2010 · CA

PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER

$1,594,634
Henry Ford Health System · N01 · FY2000 · CN

Strategies for Cancer Immunotherapy Clinical Trials

$1,593,930
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Human Immune Responses to Tumor Antigens for Cancer Immunotherapy

$1,593,930
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership

$1,591,989
Grace X Ma · Temple Univ Of The Commonwealth · U54 · FY2022 · CA

RACE-RELATED GERMLINE GENETIC VARIATION AND RESPONSE TO SECONDARY HORMONAL THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

$1,587,896
Duke University · · FY2019 · Defense Health Agency

Prostate Cancer Bone Metastasis Biology and Targeting

$1,587,650
Michael R Freeman · Cedars-Sinai Medical Center · P01 · FY2019 · CA

Cancer Center Support Grant (Comprehensive)

$1,586,953
Lawrence Corey · Fred Hutchinson Cancer Research Center · P30 · FY2009 · CA

Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents

$1,586,646
Howard H Bailey · University Of Wisconsin-Madison · N01 · FY2011 · CA

Integrative Molecular Epidemiology of Human Cancer

$1,586,024
Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Molecular Gene and Radiation Therapies for Cancer

$1,585,764
Henry Ford Health System · P01 · FY2005 · CA

Integrative Molecular Epidemiology of Human Cancer

$1,585,226
Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Biomarkers in Cancer Diagnosis,Prognosis, and Therapeutic Outcome

$1,585,226
Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Physical and Biological Determinants for Optimal PDT

$1,584,723
Massachusetts General Hospital · P01 · FY2005 · CA

Comparative Modeling of Lung Cancer Prevention and Control Policies

$1,584,503
Rafael Meza · University Of Michigan At Ann Arbor · U01 · FY2019 · CA

Physicians' Health Study II: Prevention Trial of Vitamins

$1,584,282
J Michael Gaziano · Brigham And Women'S Hospital · R01 · FY2011 · CA

X-ray phase contrast imaging and MRI diffusion image processing

$1,583,577
Han Wen · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL